| Psoriasis: Treatment and Pathogenesis | Lifetime | 777 | ES 25 | 94.59 |
| Urticaria and Related Conditions | Lifetime | 883 | ES 29 | 93.77 |
| Genetic and rare skin diseases. | Lifetime | 341 | ES 17 | 93.05 |
| Autoimmune and Inflammatory Disorders | Lifetime | 594 | ES 24 | 92.23 |
| Dermatological and COVID-19 studies | Lifetime | 262 | ES 17 | 89.01 |
| Drug-Induced Adverse Reactions | Lifetime | 930 | ES 54 | 90.81 |
| Hair Growth and Disorders | Lifetime | 735 | ES 17 | 88.32 |
| Dermatological and Skeletal Disorders | Lifetime | 934 | ES 21 | 85.89 |
| Skin Diseases and Diabetes | Lifetime | 914 | ES 42 | 80.44 |
| Hidradenitis Suppurativa and Treatments | Lifetime | 755 | ES 45 | 70.65 |
| Tattoo and Body Piercing Complications | Lifetime | 325 | ES 7 | 67.59 |
| Dermatology and Skin Diseases | 2021-2025 | 163 | ES 5 | 97.49 |
| Psoriasis: Treatment and Pathogenesis | 2021-2025 | 164 | ES 8 | 96.69 |
| Urticaria and Related Conditions | 2021-2025 | 124 | ES 4 | 94.56 |
| Asthma and respiratory diseases | 2021-2025 | 479 | ES 21 | 95.59 |
| Nonmelanoma Skin Cancer Studies | 2021-2025 | 198 | ES 6 | 91.61 |
| Autoimmune Bullous Skin Diseases | 2021-2025 | 259 | ES 6 | 92.03 |
| Hair Growth and Disorders | 2021-2025 | 135 | ES 9 | 88.59 |
| Allergic Rhinitis and Sensitization | 2021-2025 | 601 | ES 30 | 90.89 |
| Contact Dermatitis and Allergies | 2021-2025 | 206 | ES 15 | 89.14 |
| Genetic and rare skin diseases. | 2021-2025 | 69 | ES 3 | 80.49 |
| Drug-Induced Adverse Reactions | 2021-2025 | 360 | ES 19 | 81.87 |
| Dermatologic Treatments and Research | 2021-2025 | 604 | ES 15 | 81.11 |
| Skin Protection and Aging | 2021-2025 | 603 | ES 22 | 79.83 |
| Pharmaceutical studies and practices | 2021-2025 | 674 | ES 17 | 78.88 |
| Cancer and Skin Lesions | 2021-2025 | 470 | ES 23 | 74.97 |
| Genital Health and Disease | 2021-2025 | 748 | ES 20 | 74.37 |
| Urologic and reproductive health conditions | 2021-2025 | 863 | ES 17 | 72.63 |
| Dermatological and COVID-19 studies | 2021-2025 | 286 | ES 15 | 69.88 |
| Cutaneous lymphoproliferative disorders research | 2021-2025 | 936 | ES 41 | 71.45 |
| Dermatological diseases and infestations | 2021-2025 | 233 | ES 8 | 69.82 |
| Hedgehog Signaling Pathway Studies | 2021-2025 | 344 | ES 8 | 67.56 |
| Autoimmune and Inflammatory Disorders | 2021-2025 | 582 | ES 27 | 68.33 |
| Vascular Malformations and Hemangiomas | 2021-2025 | 799 | ES 26 | 58.23 |
| Dermatological and Skeletal Disorders | 2021-2025 | 451 | ES 15 | 57.69 |
| IgG4-Related and Inflammatory Diseases | 2021-2025 | 819 | ES 15 | 42.99 |
| Histiocytic Disorders and Treatments | 2021-2025 | 664 | ES 13 | 40.27 |
| Chemotherapy-related skin toxicity | 2021-2025 | 676 | ES 37 | 40.95 |
| Skin Diseases and Diabetes | 2021-2025 | 754 | ES 48 | 36.46 |
| Medicine and Dermatology Studies History | 2021-2025 | 500 | ES 62 | 21.96 |